Stephens Inc. AR Sells 11,230 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Stephens Inc. AR lessened its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 51.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,513 shares of the medical technology company’s stock after selling 11,230 shares during the period. Stephens Inc. AR’s holdings in Alphatec were worth $97,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in Alphatec during the fourth quarter worth about $29,000. Nisa Investment Advisors LLC increased its holdings in Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after buying an additional 4,234 shares during the last quarter. Newton One Investments LLC purchased a new stake in Alphatec during the fourth quarter worth about $50,000. XTX Topco Ltd purchased a new stake in Alphatec during the third quarter worth about $69,000. Finally, Ballentine Partners LLC purchased a new stake in Alphatec during the fourth quarter worth about $120,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Insider Activity at Alphatec

In related news, CEO Patrick Miles sold 6,687 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $12.00, for a total transaction of $80,244.00. Following the completion of the transaction, the chief executive officer now owns 5,501,715 shares of the company’s stock, valued at approximately $66,020,580. The trade was a 0.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Sponsel sold 58,283 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the transaction, the executive vice president now directly owns 502,311 shares of the company’s stock, valued at approximately $5,379,750.81. This represents a 10.40 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 222,376 shares of company stock valued at $2,557,148. Corporate insiders own 22.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Alphatec in a report on Tuesday, January 14th. Barclays raised their price objective on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. Finally, Needham & Company LLC lifted their target price on shares of Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.56.

Alphatec Price Performance

ATEC opened at $10.74 on Monday. The firm has a 50-day moving average price of $10.37 and a 200-day moving average price of $8.11. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -8.39 and a beta of 1.43. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $16.20. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.